Combination therapy for advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new combination of two investigational drugs, BNT324 and BNT327, for people with advanced lung cancer that cannot be removed by surgery. It aims to see if the combination is safe and effective for different types of lung cancer, including non-small cell and small cell lung cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have advanced or metastatic lung cancer (non-small cell or small cell) that cannot be removed by surgery.
- You must have at least one tumor that can be measured on scans.
- You must be able to take care of yourself (no major limitations in daily activities).
- You must have a life expectancy of at least 12 weeks.
- You cannot have had certain prior treatments (like B7-H3 targeted therapy or certain antibody-drug conjugates) unless you are in a later-line treatment group.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two investigational drugs, BNT326 and BNT327, together in people with advanced non-small cell lung cancer (NSCLC) that has spread or can't be cured with local treatment. The goal is to see if the combination is safe and might help shrink tumors.
This trial tests whether adding two newer drugs (benmelstobart and anlotinib) to chemotherapy before radiation works better than radiation alone for stage III non-small cell lung cancer that cannot be surgically removed. The goal is to improve survival and control the cancer.
This trial tests a combination of a targeted chemotherapy bead injection into lung arteries, an oral anti-cancer drug, and an immunotherapy for advanced non-small cell lung cancer that has not responded to two prior treatments. It aims to see if this triple approach can help patients who have limited options left.
This trial is testing two new drugs (DB-1311 with BNT327 or DB-1305) in people with certain advanced or metastatic solid tumors that have not responded to prior treatments. It aims to see if the combination shrinks tumors or slows cancer growth.
This trial tests an experimental immunotherapy called BNT116, given alone or with other drugs, for people with advanced non-small cell lung cancer (NSCLC). The goal is to see if it is safe and if it can help shrink tumors.
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
Hear when a new Advanced Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.